Telix Pharmaceuticals Ltd
ASX:TLX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.14
23.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TLX stock under the Base Case scenario is 16.34 AUD. Compared to the current market price of 22.58 AUD, Telix Pharmaceuticals Ltd is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Telix Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TLX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Telix Pharmaceuticals Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Telix Pharmaceuticals Ltd
Balance Sheet Decomposition
Telix Pharmaceuticals Ltd
Current Assets | 255.3m |
Cash & Short-Term Investments | 118.8m |
Receivables | 97.3m |
Other Current Assets | 39.2m |
Non-Current Assets | 490.7m |
Long-Term Investments | 10.5m |
PP&E | 38.3m |
Intangibles | 399.5m |
Other Non-Current Assets | 42.5m |
Current Liabilities | 258.4m |
Accounts Payable | 22.3m |
Accrued Liabilities | 67.3m |
Other Current Liabilities | 168.8m |
Non-Current Liabilities | 83.6m |
Long-Term Debt | 18.4m |
Other Non-Current Liabilities | 65.2m |
Earnings Waterfall
Telix Pharmaceuticals Ltd
Revenue
|
645.7m
AUD
|
Cost of Revenue
|
-246.6m
AUD
|
Gross Profit
|
399m
AUD
|
Operating Expenses
|
-325.4m
AUD
|
Operating Income
|
73.7m
AUD
|
Other Expenses
|
-24.5m
AUD
|
Net Income
|
49.2m
AUD
|
Free Cash Flow Analysis
Telix Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
The company maintains its planned R&D expenditures around $100-$105 million, with additional costs for preparing commercial manufacturing once two new diagnostic assets are approved. Current trials show good tolerance in patients, with results expected early next year. While hoping for a priority review of their breakthrough designation, the official PDUFA goal date is yet to be finalized. The contingent consideration regarding a technological acquisition reflects a percentage of 12-month sales, already accounted for in the balance sheet, indicating clear expectations from Illuccix sales, capped upon certain preconditions.
What is Earnings Call?
TLX Profitability Score
Profitability Due Diligence
Telix Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Telix Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
TLX Solvency Score
Solvency Due Diligence
Telix Pharmaceuticals Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Telix Pharmaceuticals Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLX Price Targets Summary
Telix Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for TLX is 26.46 AUD with a low forecast of 21.82 AUD and a high forecast of 35.07 AUD.
Dividends
Current shareholder yield for TLX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TLX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 158 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The firm's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.
Officers
The intrinsic value of one TLX stock under the Base Case scenario is 16.34 AUD.
Compared to the current market price of 22.58 AUD, Telix Pharmaceuticals Ltd is Overvalued by 28%.